VIVUS (STU:VIU1) EBIT per Share : €-0.74 (TTM As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS EBIT per Share?

VIVUS's EBIT per Share for the three months ended in Mar. 2020 was €-0.17. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2020 was €-0.74.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for VIVUS's EBIT per Share or its related term are showing as below:

STU:VIU1's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

VIVUS's EBIT for the three months ended in Mar. 2020 was €-1.85 Mil.

VIVUS EBIT per Share Historical Data

The historical data trend for VIVUS's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS EBIT per Share Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EBIT per Share

Get a 7-Day Free Trial

-5.28

5.08

0.22

-0.25

-0.91

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
EBIT per Share	Get a 7-Day Free Trial															-0.34	-0.17	-0.10	-0.29	-0.17

VIVUS EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

VIVUS's EBIT per Share for the fiscal year that ended in Dec. 2019 is calculated as

	EBIT per Share		(A: Dec. 2019 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.679	/	10.641
=	-0.91

VIVUS's EBIT per Share for the quarter that ended in Mar. 2020 is calculated as

	EBIT per Share		(Q: Mar. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.845	/	10.649
=	-0.17

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.74

VIVUS (STU:VIU1) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

VIVUS EBIT per Share Related Terms

Thank you for viewing the detailed overview of VIVUS's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines